VJHemOnc Podcast

In this week’s VJHemOnc podcast, we’ll be sharing highlights in myeloproliferative neoplasms (MPNs) from the recent 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025. First, you will hear a roundtable discussion, in which Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Donal McLornan, MB, BCh, MRCP, PhD, FRCPath, University College London Hospitals, London, UK, and Haifa Kathrin Al-Ali, MD, Krukenberg Cancer Center, Halle, Germany, provide insight into novel approaches for the upfront management of myelofibrosis. The experts discuss the need to define a suboptimal response to therapy and outline some of the agents being investigated for myelofibrosis in the frontline setting. Following this, Alexander Lyon, MA, BM, BCh, PhD, FRCP, FHFA, Royal Brompton Hospital, London, UK, discusses cardiovascular health in patients with MPNs, and Adrián Mosquera Orgueira, MD, PhD, Santiago Clinic Hospital CHUS, Santiago, Spain, provides insight into the application of artificial intelligence (AI) in the MDS/MPN setting. The post iwMPN 2025 highlights: novel approaches to the upfront management of myelofibrosis, cardiovascular health in MPNs, & more appeared first on VJHemOnc.

In this episode of the VJHemOnc podcast, we are joined by experts Kathryn Tringale, MD, UC San Diego Health, San Diego, CA, and Nikita Dave, MD, University of Pennsylvania, Philadelphia, PA, who share their perspectives on the management of patients with central nervous system (CNS) lymphoma from the 18th International Conference on Malignant Lymphoma (ICML 2025). The discussion covers both primary and secondary CNS lymphoma, providing practical recommendations and guidelines for oncologists, as well as highlighting emerging therapies currently under investigation. The post Managing CNS lymphoma: expert insights and updates from ICML 2025 appeared first on VJHemOnc.

VJHemOnc recently attended the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon, Portugal. This episode features experts Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, Elizabeth Griffiths, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, Lisa Pleyer, MD, Paracelsus Medical University, Salzburg, Austria, Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, and Yasushi Miyazaki, MD, Nagasaki University, Nagasaki, Japan. They begin by summarizing the key themes from their presentations, which cover a wide range of hot topics, including the role of allotransplant in Japan, communicating about drug efficacy in clinical trials, validating response criteria, and optimizing the use of hypomethylating agents. They then have an insightful discussion on how we can enhance clinical trial design and ultimately improve outcomes for patients with MDS. The post iwMDS wrap-up: translating research into practice to optimize patient care appeared first on VJHemOnc.

Today’s episode of the VJHemOnc podcast focuses on the targeting of mutant calreticulin (mutCALR) in myeloproliferative neoplasms (MPNs) – a trending topic in the field! You will hear leading experts Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, discuss what makes mutCALR an attractive therapeutic target in MPNs. Following this, John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, and Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, outline the early results of the clinical trial investigating a mutant CALR-targeted antibody, INCA33989, which were presented as a late breaking abstract at the recent 30th Congress of the European Hematology Association (EHA). Additionally, Prof. Harrison comments on other targeted therapies being evaluated in MPNs. Finally, Alex Rampotas, MBBS, MRCP, University College London, London, UK, and Zoë Wong, BSc, University of Oxford, Oxford, UK, provide insight into the development and evaluation of a novel CAR T-cell therapy targeting mutCALR in myelofibrosis (MF). The post Targeting mutant CALR in MPNs with antibodies & cellular therapy: the potential for disease modification appeared first on VJHemOnc.

This episode of the VJHemOnc podcast focuses on the treatment of elderly or unfit patients with acute myeloid leukemia (AML). Featuring experts Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Gail Roboz, MD, Weill Cornell Medicine, New York City, NY, Marina Konopleva, MD, PhD, Albert Einstein College of Medicine, New York City, NY, Joshua Zeidner, MD, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, Nelli Bejanyan, MD, Moffitt Cancer Center, Tampa, FL, Parastoo Dahi, MD, MS, Memorial Sloan Kettering, New York City, NY, and Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania. They discuss the current standard of care in the frontline setting, considerations for transplant eligibility, and future approaches being explored, such as triplet combinations including targeted agents.   The post Treating elderly or unfit patients with AML: current approach and future directions appeared first on VJHemOnc.

Explore groundbreaking advancements in hematologic oncology from the recent ASCO annual meeting. Discover promising clinical trial results in multiple myeloma and myeloproliferative neoplasms, including significant findings on rusfertide and ematelstat. Learn about innovative strategies in non-Hodgkin lymphoma and CLL, with impressive survival rates for patients treated with zanabrutinib. Additionally, uncover exciting progress in BPDCN treatment, highlighting a remarkable 70% complete remission rate with a novel antibody drug conjugate. This is a treasure trove of cutting-edge medical insights.

George Vassiliou, a Professor at The University of Cambridge specializing in clonal hematopoiesis, engages in a riveting discussion on CHIP and CCUS. He highlights the role of liquid biopsies in detecting these precursor conditions and the significance of early intervention. The conversation also covers the independent risks of monoclonal B-cell lymphocytosis alongside CHIP, showcasing how these can elevate the risk of lymphoid malignancies. The experts ponder the balance between the anxiety of treatment and the advantages of preventative measures in managing these conditions.

Morie Gertz, a leading amyloidosis expert from the Mayo Clinic, discusses the complex world of diagnosing this rare disease. He highlights early signs often missed by clinicians and elaborates on the key differences between light chain and ATTR subtypes. The conversation dives into diagnostic challenges, the role of advanced imaging, and the importance of a holistic approach to patient care. Gertz also explores emerging therapies and the significance of timely diagnosis to prevent irreversible organ damage.

Explore the intricacies of managing paroxysmal nocturnal hemoglobinuria (PNH) with insights from leading experts. Learn about the challenges of transitioning from anti-C5 to proximal complement inhibitors and the complexities of stopping anticoagulation therapy. Delve into the specialized care required for pregnant patients and discover advances in treatments like ravulizumab compared to eculizumab. The discussion also highlights the critical risks of thrombosis in PNH and effective preventive strategies to improve patient outcomes.

Join Dr. Graham Collins from Oxford University Hospitals, a lymphoma expert, as he delves into groundbreaking treatments for Hodgkin lymphoma. He highlights the shift towards newer regimens like nivolumab-AVD and BV-AVD, showcasing their potential to improve patient outcomes. The discussion touches on the complexities of managing relapsed disease, emphasizing innovative strategies that may reduce reliance on stem cell transplants. Exciting insights into ongoing clinical trials further illuminate the future of Hodgkin lymphoma therapies.